Adolescent With Severe Obesity Whose Family Declines Pharmacotherapy
A 15-year-old girl with BMI 35.6 kg/m² (weight 96 kg, height 1.64 m) and no diabetes (A1c 5.5%) is referred for weight management. She has been bullied at school and reports low mood but denies suicidal ideation. Her parents are skeptical of 'weight-loss drugs' and want a 'natural' approach. She has completed a 6-month family-based lifestyle program with no meaningful change. She is otherwise healthy, with no eating disorder history on screening. Her parents ask whether anything else can be done and whether medication is 'safe for a teenager.'
1. What is the evidence-based approach for this adolescent, and how do you address the parents' concerns?
Read the worked answer
Evidence base. For adolescents with severe obesity who have not responded to lifestyle intervention, pharmacotherapy is guideline-endorsed. Semaglutide 2.4 mg was studied in adolescents aged 12–17 with obesity and produced substantial BMI reduction versus placebo; it is FDA-approved for this age group. Metabolic and bariatric surgery is also guideline-endorsed for severe adolescent obesity meeting criteria. Lifestyle intervention alone has limited durable efficacy in this population.
Addressing concerns.
- Acknowledge that 'natural' is understandable and that lifestyle remains foundational - but explain that for severe obesity, lifestyle alone rarely produces durable change and delay has costs.
- Frame medication as treating a chronic disease, not a shortcut.
- Discuss known risks (GI side effects, need for monitoring, unknown long-term effects) honestly and the risks of untreated severe obesity (persistent obesity into adulthood, diabetes, bullying, mood effects).
- Use shared decision-making with the adolescent's own voice included.
Judgment. Do not abandon the conversation when parents decline; document, offer a defined review point, and keep the door open.
2. The family agrees to 'think about it.' What safety and monitoring issues must be addressed before any pharmacotherapy is started in this patient?
Read the worked answer
Mental health. Screen formally for depression, suicidal ideation, and disordered eating (e.g., binge eating) before and during treatment; low mood and bullying are relevant. Coordinate with behavioral health.
Contraindications and screening. Personal or family history of medullary thyroid carcinoma or MEN2 (absolute contraindication for GLP-1 agents); history of pancreatitis; gallbladder disease; and pregnancy status - counsel on contraception, as these agents are not for use during pregnancy and should be stopped before conception.
Growth and development. Track height, weight, BMI, and pubertal development; ensure nutritional adequacy during reduced intake.
Logistics. Confirm the family can attend follow-up and afford the medication; set a response threshold and review date.
Judgment. The safety work-up and the family's decision timeline should be planned together, with a scheduled follow-up rather than an open-ended 'think about it.'